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Study objectives: To calculate incremental cost–utility ratios (cost per QALY gained) for
varenicline (Champix; Pﬁzer), as compared to bupropion, in smoking-cessation pro-
grammes for a lifetime follow-up period.
Design: The Beneﬁts of Smoking Cessation on Outcomes (BENESCO) simulation model was
used for a male and female cohort, respectively, as a point of departure but further
extended in order to include the indirect effects of smoking-cessation on production and
consumption in the economy. All calculations were performed in 2003 Swedish prices.
Setting: Sweden in 2003.
Patients or participants: Model cohort consisting of 25% of all smokers among men and
women (168,844 males and 208,737 females), distributed by age, 18 and older, as in the
Swedish population of 2003.
Interventions: Varenicline as compared to bupropion, in smoking-cessation programmes
for 20-year, 50-year, and lifetime follow-up periods.
Measurements and results: When the indirect effects on production and consumption
were included, the incremental costs per QALY gained were h2056 (h14,743) for men and
h1193 (h14,214) for women, in comparison to bupropion and computed for a time horizonElsevier Ltd. All rights reserved.
disease; COPD, chronic obstructive pulmonary disease; BENESCO, Beneﬁts of Smoking Cessation on
onsequences of Smoking; ICUR, incremental cost–utility ratio; NRT, nicotine replacement therapy;
Underso¨kningar av Levnadsfo¨rha˚llanden (Swedish Survey of Living Conditions).
versity Centre for Health Economics, P.O. Box 705, SE-220 07 Lund, Sweden. Tel.: +46 46 2220654;
che.lu.se (K. Bolin), ann-christin.mork@pﬁzer.com (A.-C. Mo¨rk), stefan.willers@med.lu.se (S. Willers),
n).
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K. Bolin et al.700of 20 and 50 years (1hEhSEK9.12). Excluding the indirect effects on production and
consumption, varenicline was cost-saving in comparison to bupropion. Sensitivity analysis
indicated that the results are robust. Variation of treatment efﬁciency and intervention
costs, respectively, had a larger effect on cost per QALY gained than other variables.
Conclusions: Estimated costs per QALY gained rated smoking-cessation intervention using
varenicline among the most cost-effective life-saving medical treatments.
& 2008 Elsevier Ltd. All rights reserved.Introduction
The adverse impact of tobacco smoking on health has been
reported in the literature at least since the early 1950s.1
Nowadays, available epidemiological evidence concerning
the relative risks associated with smoking make it possible
to estimate the beneﬁts of smoking-cessation in terms of
avoided consequences of smoking-related morbidity and
mortality, granted that the risks for former smokers
approach those of non-smokers over time.
Several studies quantify the costs accruing as a result of
smoking.2–5 This evidence suggests that smoking-cessation
health programmes are potentially beneﬁcial. Whether or
not additional resources spent on a smoking-cessation
programme are worthwhile depends, however, on the extent
to which there will be sufﬁciently large subsequent
reductions in the (net) costs imposed by smoking on the
economy (reduced costs for healthcare associated with
smoking-related morbidity, reduced productivity losses
induced by smoking-related mortality, and increased
health-related quality of life).
Available smoking-cessation therapies involve—apart
from counselling without any drug—various nicotine repla-
cement therapies and bupropion. With the introduction of
varenicline, a non-nicotine-based substance, clinicians now
have a new class of pharmaceuticals at their disposal in
smoking-cessation therapy.6 Varenicline was developed
especially for the purpose of smoking-cessation; it is a
partial agonist at the a4b2 nicotinic acetylcholine receptor
in the brain, and as such it both relieves symptoms of
nicotine withdrawal and cigarette craving, and reduces the
rewarding properties of nicotine.7,8 In the summer of 2006,
JAMA published two randomised studies of varenicline’s
clinical efﬁcacy, compared to bupropion as an aid in
smoking-cessation therapy.7,8 Those who utilised varenicline
were more likely to remain non-smokers over a 12-month
period than those who used bupropion. Moreover, in a
parallel study it was found that a longer treatment period
with varenicline signiﬁcantly increased the success rate of
smoking-cessation therapy.9 Buproprion has previously been
found to be a cost-effective alternative to nicotine
replacement therapies, and in a recent study varenicline
was compared to bupropion in a Dutch setting.10,11
The Beneﬁts of Smoking Cessation on Outcomes Model
(BENESCO) is a recently developed discrete and determinis-
tic simulation model that predicts smoking-related morbid-
ity and mortality and the corresponding healthcare costs.11
The structure and functioning of the model rests on the
same principles as those behind the Health Economic
Consequences of Smoking (HECOS) simulation model, which
was prepared for and reviewed by the World HealthOrganisation European Partnership Project to Reduce To-
bacco Dependence.12
In this paper, we report on the cost–utility of using
varenicline (Champix; Pﬁzer) compared to bupropion in
smoking-cessation programmes in Sweden. Even though the
net beneﬁts of smoking-cessation in Sweden might differ
from the beneﬁts in other countries, our detailed account of
input data will certainly facilitate comparisons with other
settings. It should be possible to conclude whether the
cost–utility ratios would be higher or lower in a country with
which the reader is more familiar. Another objective of the
paper was to show the general usefulness of the simulation
model as such.
The BENESCO model was utilised, taking the year 2003 as
our point of departure, in order to simulate the conse-
quences of smoking-cessation therapy in Sweden. We
expanded the model to include indirect costs.Method and material
Simulation model
Even though the BENESCO model and the HECOS model are
founded on the same principles, there is one important
difference: while the HECOS model applies published
relative risks of dying from smoking in order to calculate
smoking-attributable morbidity and mortality, the BENESCO
model—using the same published risks—simulates total
morbidity and mortality associated with the same diseases.
The BENESCO model estimates the relative effects on
morbidity and mortality of smoking-cessation, utilising a
particular therapy, as the difference between morbidity and
mortality when that therapy is being used and morbidity and
mortality when a competing therapy is being used.
The BENESCO model simulated the lifetime development
of morbidity and mortality for a Swedish population of
smokers, aged 18–100. The simulations assumed that 25% of
the smokers in each age group, and for men and women,
respectively, make one attempt to quit smoking at the
outset of the simulation; this amounts to 168,844 men and
208,737 women. In order to simplify calculations without
substantially affecting results, it was assumed that no one
smoked below the age of 18 and that so few would live after
a 100 years of age that, for our purpose, they could be
neglected completely. The simulation took smoking habits
and the prevailing age-, morbidity-, and mortality structure
in the total 18–100 years-old Swedish population (3,593,732
men and 3,728,987 women) in the year 2003 as the point of
departure. Absolute risks of developing and/or dying from
each of the considered diseases were calculated for smokers
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entered into the simulation of post-smoking-cessation-
intervention morbidity and mortality, assuming no smok-
ing-related morbidity or mortality in the population below
the age of 35.
The model distinguished between men and women in
three age groups: (a) 18–34; (b) 35–64; and (c) 65 and olderTable 1 Data description.
Disease- and age-
speciﬁc incidence-,
prevalence-, and
mortality rates
Estimates were based on individual dat
administrative registers of the Swedish
incidence rate was estimated as the nu
respective diagnosis in 2003. Second, th
living individuals in 2003, which had ev
number of individuals in the inpatient c
year 1987 and onwards; each individual
Third, regarding the CHD and stroke dia
between ﬁrst and subsequent events an
from the total number of events (total
estimated from the total mortality estim
admitted to hospital due to CHD and st
Mortality rates in
the general
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Estimates were based on life tables pro
Estimated average
annual healthcare
cost by disease
The only (Swedish) morbidity-related he
outpatient care and (2) are gathered sy
The county of Ska˚ne has approximately
and is demographically similar to the to
investigation concerning the compensat
benchmark.21 More speciﬁcally, the inpa
to corresponding data from the county
National Board of Health and Welfare, a
estimates were based on individual diag
occurring in the county of Ska˚ne.22 The
COPD, CHD, stroke or lung cancer was f
the ﬁrst year following diagnosis was us
average cost during the second and thir
subsequent years. The costs for prescrib
information from a representative samp
pharmaceuticals associated with stroke
Further, data were not available for late
stroke patient rehabilitation was added
estimates do not include institutional o
QALY weights Equal utility weights were used for quitt
does not incorporate any quality-of-life
utility weights are provided as default a
utility weights supplied by Spencer et a
with the information on COPD severity a
calculate a single utility weight for COP
utility weight applied to the ﬁrst year a
subsequent years. The utility weights w
with myocardial infarction and angina p
DG, Dasbach EJ, Klein R, et al. The Bea
state quality factors. Med Decis Making
calculating a weighted average of the u
were based on the prevalence of MI and
weights supplied by Tengs and Lin for se
information on stroke severity providedas well as between three health states: (A) no morbidity,
(B) morbidity, and (C) dead. With respect to morbidity/
mortality risk, the model also distinguished between
(1) current smoker; (2) recent quitter-stopped smoking
between 1 and 5 years ago; and (3) long-term quitter-
abstinent for at least 6 years. As regards the risk of relapse,
the model distinguished between (1) those attempting toa on inpatient care and causes of death from the
National Board of Health and Welfare.18,19 First, the
mber of individuals, who received inpatient care due to
e prevalence of each disease was estimated as the number of
er received inpatient care due to respective diagnosis (the
are register, for respective diagnosis, was counted from the
was controlled for against the register of causes of death).
gnoses, respectively, the simulation model distinguished
d, hence, ﬁrst-incidence events were reported separately
incidence). Finally, the number of ﬁrst-event deaths was
ates subtracting those that in previous years had been
roke, respectively
vided by Statistics Sweden20
alth-care cost-data that (1) include both inpatient- and
stematically, are the data collected in the county of Ska˚ne.
1.2 million inhabitants (13% of the total Swedish population)
tal Swedish population. Moreover, the governmental
ion system between counties used the Ska˚ne data as a
tient-care cost-data from the county of Ska˚ne was compared
of Stockholm and inpatient-care register data from Swedish
nd no signiﬁcant differences were revealed. Thus, our
nosis-related data on all inpatient stays and outpatient visits
healthcare consumption of all individuals diagnosed with
ollowed during a period of 3 years. The average cost during
ed as an estimate of the ﬁrst-year healthcare cost; the
d years as an estimate of the healthcare costs during
ed pharmaceuticals were estimated, using diagnosis-related
le of 6.25% of all physicians in Sweden.23 Data on prescribed
and lung cancer, respectively, were not available, though.
r years than 2002. The cost of ﬁrst- and subsequent years of
, using estimates presented by Ghatnekar et al.24 Our
r informal care, though, due to lack of data
ers and smokers with no morbidity, i.e., the simulation model
inﬂuence of smoking cessation per se.25 Morbidity-speciﬁc
lternatives in the BENESCO simulation model: for COPD, the
l. for severe, moderate and mild COPD were used together
s provided by Mannino et al., and Spencer et al., in order to
D.26,27 For lung cancer, the simulation model allows for the
fter diagnosis to differ from the utility weight applied to
ere provided by Trippoli et al.28 Utility weights associated
ectoris were reported by Hay and Sterling (refers to Fryback
ver Dam Health Outcomes Study: initial catalogue of health-
1993;13:89–102).29 A utility score for CHD was obtained by
tility associated with MI and angina pectoris. The weightings
angina pectoris in those with CHD.30 For stroke, the utility
vere, moderate and minor stroke were used together with
by Duncan et al31,32
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Table 1. (continued )
Intervention cost Estimates followed general recommendations on drug dosage, and Swedish clinical practice on
motivational support in smoking-cessation. However, as for motivational support or the appropriate
combination of drugs and motivational support, no formal guidelines were available.33 Clinical
practice in Sweden varies, since smoking-cessation interventions may be provided both in primary-
and in specialised healthcare, implying great variety both in personnel characteristics and in the mix
of healthcare contacts and drugs. There are, however, two critical differences between varenicline
and bupropion, which are important for determining the cost of intervention. First, the prescription
of bupropion is conditioned on mandatory motivational support, which is not the case for varenicline.
This may make prescribers relatively more inclined of providing motivational support in the
bupropion case.34 Second, the medical investigation preceding prescription is less complex in the
varenicline case compared to the bupropion case, since varenicline has fewer contraindications and
interactions.35 Thus, smoking-cessation therapy using varenicline is likely to be less healthcare
intensive than the bupropion alternative, and in our baseline case, smoking-cessation interventions
using bupropion comprised two additional motivational support visits to a nurse as compared to a
smoking-cessation programme using varenicline. Men and women were treated identically with
respect to the cost of the smoking-cessation intervention
Smoking prevalence Estimates were based on ULF data (Underso¨kningar av Levnadsfo¨rha˚llanden) for the years 1996/
1997.36 This is consistent with how the relative risks of morbidity, which is the core piece of
information behind the simulations performed with the BENESCO model, were estimated—with a
follow-up period of 6 years (Thun et al.15)
Treatment
effectiveness
The estimate of treatment effectiveness was based on two identically designed, head-to-head
trials—Gonzales et al.7 and Jorenby et al.8—of the efﬁcacy of varenicline as compared to bupropion
in smoking-cessation therapy. The studies employed identical inclusion and exclusion criteria, and
included participants with close to identical characteristics. Further, the studies report 12-month
(9–52 weeks) continuous quit rates. The efﬁcacy used in the simulations is calculated from the pooled
clinical trial data8,37
Morbidity and
mortality rates of
former smokers
Recent quitters—those who stopped smoking less than a year ago—were assumed to face the same
risks of morbidity and mortality as current smokers. Medium-term quitters—those who stopped
smoking between 1 and 5 years ago—were assumed to enjoy a relative risk of smoking-related
morbidity and mortality consistent with those reported for former smokers.15 Long-term
quitters—those who had been abstinent for at least 6 years—were assumed to face the same relative
risks as never-smokers (strictly speaking, the difference between relative risks faced by long-term
quitters and never smokers get smaller over a longer period of time, but are negligible after 6 years)
Relapse rates For recent quitters, we assumed that the individual would face the particular risk of relapse
associated with the smoking-cessation therapy selected during the ﬁrst year of being abstinent. For
medium-term quitters, we assumed that the individual would face a 6% annual risk of relapsing into
smoking.38 For long-term quitters, we made separate assumptions for those who had been abstinent
6–10 years and for those who had been abstinent for more than 10 years. For the ﬁrst group we
assumed a 2% annual risk of relapsing, for the latter a 1% annual risk39
Average net value
of the indirect
effects
A module on the indirect effects on production and consumption was added, using estimates provided
by Ekman (2002).40,41 The age groups in Ekman’s study did not match those used in the BENESCO
simulation model perfectly, but we calculated the value for the age group 35–65 by weighting the
values reported for the age groups 35–49 and 50–64 by their respective share of the population in the
same age groups. The difference between the values of production and consumption for those older
than 65 years of age was estimated analogously
Discounting A 3% rate was used for both costs and effects in the baseline analysis
Each input component utilised in the simulations performed by the BENESCO model is described regarding source and content.
K. Bolin et al.702quit (the ﬁrst year); (2) recent quitters—stopped smoking
between 1 and 5 years ago; (3) medium-term quitters—
stopped smoking in between 6 and 10 years ago; and (4)
long-term quitters—stopped smoking more than 10 years
ago.
Four diseases were considered: (1) COPD (chronic
obstructive pulmonary disease), (2) CHD (coronary heartdisease), (3) stroke, and (4) lung cancer. Together they
cover most of the health problems associated with smoking,
according to present epidemiological knowledge, even
though there are other smoking-related diseases, too.11,12
For example, recently established associations between
smoking and gastric cancer (about doubled risk) and
rheumatoid arthritis, both with very expensive treatments,
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Table 2 Data on estimated sex- and age-speciﬁc prevalence, incidence, and mortality (total numbers), annual morbidity-related healthcare costs per person, and QALY
weights, by disease.
Prevalence Incidence Mortality Healthcare costs
(h; 1hESEK9.12)
QALYs weights
Age group 18–34 35–64 65+ 18–34 35–64 65+ 18–34 35–64 65+ First year/
(subsequent years)
First year/
(subsequent years)
COPD
Men 1,016 3,319 11,353 17 766 4,023 2 89 1,320 3,199 0.76
Women 687 4,595 13,672 18 1,164 4,318 2 130 1,214
Lung cancer
Men 31 815 1,763 6 747 1,601 2 475 1,330 11,397 (6,056) 0.61 (0.50)
Women 31 1,054 1,557 8 782 1,123 3 431 902
Total/(ﬁrst event) All/(ﬁrst event) First year/
(subsequent event)
First event/
(subsequent years)
CHD
Men 217 54,384 120,692 59 (49) 10,144 (6,392) 19,812 (10,092) 6 (6) 1,359 (1,043) 9,098 (5,236) 5,278 (1,513) 0.76 (0.76)
Women 98 19,746 85,654 27 (24) 3,751 (2,537) 16,328 (9,489) 3 (3) 364 (301) 8,357 (5,677)
Stroke
Men 445 14,558 49,292 64 (55) 2,718 (2,315) 9,611 (7,395) 0 (0) 210 (180) 1,472 (1,015) 8,643 (2,074) 0.74 (0.15)
Women 445 8,273 49,464 55 (48) 1,481 (1,281) 10,953 (8,824) 3 (0) 106 (98) 1,993 (1,491)
Data sources: National Board of Health and Welfare (prevalence, incidence, and mortality); Region Ska˚ne (treatment costs).
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Table 4 Data of age-speciﬁc smoking-prevalence rates
and quit rates in percent, and estimated indirect effects
(the value of consumptionvalue of production) in
Sweden 2003.
Smoking/former smoker prevalence
Men 18–34 15%/6.2%
Men 35–69 22%/11.0%
Men 70+ 15%/7.2%
Women 18–34 23%/10.3%
Women 35–69 27%/8.7%
Women 70+ 13%/4.5%
Quit rates
K. Bolin et al.704were not considered.13,14 As regards CHD and stroke, the
modelling was more elaborated than what are the cases for
COPD and lung cancer, respectively. CHD and stroke are both
characterised by acute and recurring events at which cases
treatment is relatively costly, while COPD and lung cancer
are progressive (and chronic) events. Moreover, the mortal-
ity risk associated with both CHD and stroke, conditional on
that the individual already suffered an event, differs from
that for smokers in general. These qualiﬁcations were
incorporated in the BENESCO simulation model.
More formally, the BENESCO simulation could be thought
of as employing discrete difference equations, when the
distribution of the population over the states of the model in
each year is calculated. The transitions from one state to
another are represented by rates of change. The propor-
tions, which transit from one state to another, are
calculated, given population-speciﬁc smoking habits and
morbidity- and mortality rates. Smoking habits are given by
quit rates (efﬁcacy) of the intervention; morbidity and
mortality are calculated using relative risks of dying from
each particular disease. Each year, 1/16th of the smokers in
the 18–34 age group moves to the 35–64 age group and,
hence, acquires the same morbidity- and mortality risks as
those in the 35–64 age group. Similarly, at the end of each
year, 1/29th of the smokers in the 35–64 age group advances
to the 65+ age group. The number of smokers in each state
at time t+1, Ntþ1i (i ¼ 1, y, 7), can be expressed by the
following discrete difference equation:
Ntþ1i ¼ Nti þ Ntj!i  Ntj i, (1)
where Ntþ1j!i is the number of individuals who move to state i
and Ntþ1j i is the number of individuals who leave state i.
15–17
The model performs simultaneous but separate calcula-
tions for the intervention strategy and a chosen comparator
strategy. The proportions of smokers who move between
different smoking-states were calculated, using (1) esti-
mates of the effectiveness of the different treatment
strategies, (2) estimates of the morbidity rates associ-
ated with being a smoker, a recent quitter, a medium-
term quitter, or a long-term quitter, respectively, and
(3) information regarding mortality rates.Varenicline 22.5%
Bupropion 15.7%
Indirect effects (the value of consumption—the value of
production)
Age group: 35–64 9,523
Age group: 65+ 17,463
h; 1hESEK9.12.Data
The simulation model was provided with the following input
data for men, women, and age groups: (1) prevalence-,
incidence-, and mortality rates of each of the diseases
considered; (2) mortality rates in the total population;
(3) average annual direct healthcare costs by diseaseTable 3 Data of intervention cost per person for the different
Varenicline (12 weeks treat
Drug cost h233 (1mg BID)
GP visit h123; 1 visit (primary care)
Motivational support (nurse) h96 (2 48); 2 visits (prima
Total cost h452
h; 1hESEK9.12.(COPD: h3199; lung cancer: h11,397 (ﬁrst year); CHD:
h5278 (ﬁrst year); stroke: h8643 (ﬁrst year)); (4) QALY
weights; (5) intervention costs (varenicline alternative:
h452; bupropion alternative: h419); (6) smoking prevalence;
(7) treatment effectiveness (varenicline alternative: 22.5%;
bupropion alternative: 15.7%); (8) morbidity and mortality
rates of former smokers; (9) relapse rates; and (10) average
net value of the indirect effects (consumption—produc-
tion). A detailed description of the content of the input data
can be found in Table 1 and following Tables 2–4, which
specify the input data.7,8,15,18–41Sensitivity analyses
No data are perfect; hence, all estimates are subject to
some uncertainties. In order to assess the extent to which
our results were sensitive to the various assumptions made
and since traditional statistical conﬁdence intervals were
not possible to calculate due to lack of data, we re-
estimated the incremental cost–utility ratio (ICUR) for
various values of the input variables.
Both univariate and bivariate, non-stochastic as well as
stochastic, sensitivity analyses were performed. While non-
stochastic sensitivity analyses are useful for examining the
range of a speciﬁc variable for which the ICUR falls below a
speciﬁed threshold value, they contain no information as tosmoking cessation interventions in Sweden 2003.
ment) Bupropion (7 weeks treatment)
h104 (150mg BID)
h123; 1 visit (primary care)
ry care) h192 (4 48); 4 visits (primary care, nurse)
h419
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below that threshold value. The BENESCO simulation model
incorporates a facility, which makes it possible to perform
Monte Carlo simulations of the ICUR, using available
information concerning the distribution and its character-
istics for the parameters entering the calculation of
the ICUR. In effect, these simulations produce an esti-
mate of the likelihood distribution of the ICUR. Our
stochastic sensitivity analysis included Monte Carlo simula-
tions regarding three variables: (1) effectiveness of the
smoking-cessation therapies under consideration, (2) mor-
bidity-related healthcare costs, and (3) utility weights.Results
Baseline case
Table 5 shows the baseline-case results of the 20- and
50-year-period simulations for the male and female popula-
tions, respectively. Results are reported separately for:Table 5 Results: baseline. Total incremental intervention cost
total QALYs gained, and the incremental cost per QALY gained. Re
respectively, in each case separately for the male and female p
Varenicline vs. bupropion 20 years
Including indirect
effects
Men
Incremental intervention cost 5 458,518
Healthcare cost averted 13 196,719
Indirect cost averted 13 065,853
QALYs gained 2,591
Incremental cost per QALY gained 2,056
Women
Incremental intervention cost 6 748,210
Healthcare cost averted 16 206,542
Indirect cost averted 12 386,576
QALYs gained 2,455
Incremental cost per QALY gained 1,193
h; 1hESEK9.12.
Table 6 Results of univariate non-stochastic sensitivity analysi
period simulation results for the male and female populations, r
Follow-up period
2 years
Men
Including indirect effects 390,108
Excluding indirect effects 388,136
Women
Including indirect effects 686,360
Excluding indirect effects 682,902
h; 1hESEK9.12.(1) total incremental intervention cost (the additional cost
imposed by using varenicline instead of bupropion), (2) total
healthcare cost averted (the cost saved in the healthcare
sector from using varenicline instead of bupropion—
a negative sign indicates that this amount was subtracted
from the total incremental cost), (3) total indirect cost
averted (indirect cost is the difference between gains in
production- and consumption values induced by life years
saved, as a result of using varenicline instead of bupropion—
a positive sign indicates that this amount was added
to the total incremental cost), (4) total QALYs gained
(the number of life years saved adjusted for the loss of
health-related quality of life implied by the disease), and
(5) the incremental cost per QALY gained, i.e., the sum of
(1)–(3) divided by (4). Results are reported separately for
men and women. All costs are in 2003 Swedish prices (SEK).
The estimated cost per QALY gained ranged from h1193
(women, and a 20-year period) to h14,743 (men, and a
50-year period), indirect effects included. Excluding the
indirect effects, i.e. focusing on healthcare costs only,
would make varenicline a dominating, cost-saving, option., total healthcare cost averted, total indirect cost averted,
sults are reported for a 20- and a 50-year period simulation,
opulations, Sweden 2003.
50 years
Excluding
indirect Effects
Including indirect
effects
Excluding
indirect effects
5 458,518
21 310,726
115 747,143
6,776
2,987 14,743 2,340
6 748,210
-30 755,847
133 554,718
7,707
3,852 14,214 3,115
s: the incremental cost per QALY gained (2-, 5-, and 10-year
espectively, Sweden 2003).
Lifetime
5 years 10 years (80 years)
28,002 3,908 16,120
24,129 523 2,298
48,939 5,452 18,582
45,028 2,103 3,052
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Table 8 Results of univariate non-stochastic sensitivity analysis: the incremental cost per QALY gained for alternative
discount rates, QALY weights, intervention cost, effectiveness, and relative risks (in all cases for 20/50 years follow-up period
for men and women, respectively, Sweden 2003).
Men Women
20 years 50 years 20 years 50 years
Discount rates
Effects: 0%; costs: 5% 1,215 3,719 858 3,277
Effects: 0%; costs: 0% 1,784 19,357 705 18,416
Effects: 5%; costs: 5% 2,376 12,294 1,712 11,947
QALY weights
COPD 0.45 1,416 11,440 743 10,293
CHD 0.48
Lung cancer 0.13
Stroke 0.36
QALY weights (high–low)
0.1 1,076 9,215 537 7,943
0.75 2,113 15,013 1,227 14,480
Intervention cost (varenicline)
Baseline+100 2,771 15,017 2,124 14,511
Baseline+500 5,628 16,109 5,851 15,588
Baseline+1000 9,199 17,474 10,509 17,182
Baseline+2000 16,340 20,205 19,826 20,150
Intervention cost–drug costs only 8,341 17,146 9,391 16,825
Effectiveness of varenicline
22.0% 2,224 14,807 1,411 14,282
21.0% 2,653 14,972 1,971 14,462
20.0% 3,281 15,212 2,791 14,723
19.0% 4,291 15,598 4,108 15,142
Relative risks (current vs. never smoker)
Lower CI (95%) 2,180 14,971 1,560 14,544
Upper CI (95%) 1,780 14,415 1,099 14,029
h; 1hESEK9.12.
Utility weights from Bolin et al. (2006).
Table 7 Results of univariate non-stochastic sensitivity analysis: the incremental cost per QALY gained (treatment costs are
varying (uniformly) from 25% to 100% more than the baseline case, Sweden 2003).
Treatment cost at baseline increment (20/50 years)
Baseline 1.25 Baseline 1.5 Baseline 1.75 Baseline 2.0
Men
Including indirect effects 783/13,957 490/13,171 1,764/12,385 3,037/11,598
Excluding indirect effects 4,260/3,126 5,534/3,912 -6,807/-4,698 8,080/5,485
Women
Including indirect effects 457/13,216 2,106/12,219 3,758/11,221 5,408/10,223
Excluding indirect effects 5,502/4,113 7,152/5,110 8,802/6,108 10,452/7,105
h; 1hESEK9.12.
K. Bolin et al.706Detailed sensitivity results are presented in Tables 6–9.
Stochastic sensitivity analyses were also performed, for a
50-year follow-up period. The results are presented in
Figures 1 and 2.Discussion
Varenicline is a new smoking-cessation drug that distin-
guishes itself from its predecessors: it works as a partial
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Figure 1 Illustrates the probability of observing a speciﬁc ICUR between 0 and h20,000 for a 50-year follow-up period, when some
of the parameters in the simulation model are regarded as produced by a stochastic process. It was assumed (a) that the
effectiveness of the smoking-cessation therapies under consideration are normally distributed16–18; (b) that the morbidity-related
health-care costs are log-normally distributed; and (c) that utility weights are beta-distributed.
Cost-Effectiveness Acceptability Curve. Women.
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Figure 2 Illustrates the probability of observing a speciﬁc ICUR between 0 and h20,000 for a 50-year follow-up period, when some
of the parameters in the simulation model are regarded as produced by a stochastic process. It was assumed (a) that the
effectiveness of the smoking-cessation therapies under consideration are normally distributed16–18; (b) that the morbidity-related
health-care costs are log-normally distributed; and (c) that utility weights are beta-distributed.
Table 9 Results: bivariate non-stochastic sensitivity analysis. The incremental cost per QALY gained, when effectiveness (of
varenicline) and intervention cost were varied simultaneously for men and women, respectively. Sweden 2003. 20/50 years
follow-up period.
Effectiveness Intervention cost (Baseline +)
100 500 1000 2000
Men
22% 2,995/15,102 6,078/16,281 9,933/17,755 17,641/20,703
21% 3,569/15,322 7,235/16,723 11,816/18,475 20,980/21,979
20% 4,411/15,644 8,929/17,371 14,576/19,531 25,870/23,849
19% 5,763/16,161 11,650/18,412 19,008/21,225 33,725/26,853
Women
22% 2,416/14,604 6,439/15,885 11,467/17,487 21,523/20,691
21% 3,166/14,842 7,947/16,366 13,924/18,270 25,877/22,078
20% 4,264/15,192 10,157/17,070 17,524/19,417 32,257/24,110
19% 6,027/15,754 13,706/18,200 23,305/21,259 42,503/27,374
h; 1hESEK9.12.
Varenicline as compared to bupropion in smoking-cessation therapy 707agonist at the a4b2 nicotinic acetylcholine receptor by both
relieving nicotine withdrawal symptoms and reducing the
rewarding properties of nicotine. In this study, we per-formed a simulation-model cost–utility analysis of a Swedish
cohort of male and female smokers. Swedish data were used
concerning (1) diagnosis-speciﬁc morbidity and mortality,
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costs, (4) impact on future consumption and production of
avoided mortality, and (5) smoking-cessation intervention
costs. The ICURs calculated range from about h1000 to 2000
(in a 20-year perspective), which is signiﬁcantly below
corresponding ﬁgures reported for treatments of relevant
chronic diseases and regarding willingness to pay for an
additional QALY.10
Incremental cost–utility ratios were calculated and
presented both including and excluding future effects on
consumption and production. The reason for this is that
there seems to be no consensus yet among decision-makers
or among economists on the correct way of doing it. Thus,
economic-evaluation guidelines used in the process of
pricing and reimbursement of pharmaceuticals differ among
countries.42 Guidelines in Sweden include future effects on
consumption and production, while, for instance, guidelines
for the UK do not.42,43 Among the economists, Meltzer,40 and
Lundin and Ramsberg,44 for instance, argue for the inclu-
sion, while Nyman,45 for instance, argues against it.
In this study, we obtained the result that the varenicline
intervention is cost-saving compared to the bupropion
intervention, taking only healthcare costs into account,
and has a positive cost-effectiveness ratio when also net
costs of increased survival are included. This partly differs
from the results obtained in previous economic evaluations
of smoking-cessation therapies.10 First, previous cost-
effectiveness and cost–utility studies have obtained both
negative and positive ratios when only healthcare costs
are considered. Thus, Bolin et al.10 reported negative
cost–utility ratios regarding the comparison between bu-
propion and nicotine gum but positive cost–utility ratios for
bupropion vs. nicotine patches, when only healthcare costs
were taken into account.10 The fundamental mechanism
here is that the initial intervention cost is recovered through
saved morbidity-related healthcare costs—the higher the
relative efﬁcacy of the interventions, the shorter time
period is needed in order to obtain a cost-saving scenario.
Second, there are relatively few cost-effectiveness studies
of smoking-cessation therapies, which include also the
effects on increased survival. In a recent study performed
for Sweden, however, Bolin et al.10 found negative costs of
survival, i.e., that the smoking-cessation therapy has a
relatively large effect for those in productive ages.10 This
stands in contrast to the results obtained here. The
discrepancy can be explained (1) by the relatively large
difference in efﬁcacy rates in this study—since the relative
risk reduction of smoking-cessation is larger for the older
age group (Thun et al.) a larger difference in efﬁcacy rates
means that relatively more people in the non-productive
ages will survive, i.e., the cost of increased survival
increases with the difference in efﬁcacy rates15; and (2)
by different age groups used in the two studies—the
simulation model used by Bolin et al. were constructed for
the age groups 35–69 and 70+, using the higher relative risk
reduction for the 70+ age group on a relatively smaller
cohort than what we have used in this study.10 Further, the
available measures of net values of production and
consumption did not allow for a corresponding division into
age groups, and, hence, the differences between the values
used here and the values used in Bolin et al. are small.10
Thus, the difference between studied cohorts translates,more or less unchanged, into differences in costs for
increased survival.
The simulations performed imply that about 9200 life
years per 100,000 smokers (which corresponds to almost 500
life years per 100,000 in the general population) are saved
when using varenicline instead of bupropion in smoking-
cessation therapy. The simulation model simulates the
population and shares of that population that move into
different states of illness: if a certain percentage of the
population stop smoking there will be (expected) illnesses
avoided today and in the future. The extent to which this
should be regarded as merely a postponement of illness, or
whether it is truly a matter of avoidance, is determined by
the age-proﬁle of relative morbidity risks of smokers
compared to non-smokers. If, for instance, the relative risk
for smokers compared to non-smokers, of getting a certain
illness, decreases with age, the decrease in the incidence
rate at the time close to the smoke stop is a postponement
of illness. If, on the other hand, the relative risk stays at
roughly the same level over the lifecycle, smoking-cessation
results in avoidance of illness. For lung cancer and COPD,
the relative risks are not declining with age, and are quite
large, suggesting that to a certain extent these illnesses are
avoided by not smoking. For CHD and stroke, on the other
hand, the relative risks are twice as high for the age group
35–64 as for those older than 64 years of age, for whom the
relative risk for smokers are close to one. This suggests that
smoking-cessation postpones these illnesses.
Future indirect effects induced by the increased survival
are valued using the values of production and consumption
reported by Ekman.41 Conveniently, the ﬁgures reported by
Ekman include the average value of health-care consump-
tion for different age groups and, hence, our calculations of
indirect effect include also future increases in health-care
costs resulting from increased survival. However, to some
extent changes in the value of consumption were double-
counted: the health-care consumption included in the
values above is the average value taken over all types of
health-care consumption, while the health-care consump-
tion included in the direct cost-component comprises
disease-speciﬁc consumption. In addition, our method
overestimated the true indirect effects for the age group
35–65, since some of the individuals who died would not
have been active in the labour market anyway, due to their
illness. To some extent this is offset, since these individuals
would have evoked larger than average direct health-care
costs, had they not died. Likewise, our method under-
estimated the true indirect effect of mortality for those
older than 65 years of age, since their consumption of
healthcare, had they survived, would have been higher than
average.
It should be noticed, though, that our calculations did not
take into account the effects on production and consump-
tion that will occur if individual health behaviour changes as
a result of a smoke stop. If, in general, more healthy
lifestyles result among previous smokers, a further increase
in life years saved will result. The effect of this on the
cost–utility ratio depends on the age structure of the
change—if the change in health behaviour is conﬁned to the
younger smokers the cost–utility ratio will decrease. Also,
healthier lifestyles entail less healthcare consumption,
which would lower the cost–utility ratio.
ARTICLE IN PRESS
Varenicline as compared to bupropion in smoking-cessation therapy 709Role of funding sources
This research was sponsored by Pﬁzer AB, Sweden. Kristian
Bolin, Stefan Willers, and Bjo¨rn Lindgren, were funded by
Pﬁzer AB, Sweden, in connection with the development of
this manuscript. Ann-Christin Mo¨rk is an employee of Pﬁzer
AB, Sollentuna, Sweden.Acknowledgement
The authors are grateful to Annika Edberg, Centre for
Epidemiology, the National Board of Health and Welfare,
Sweden, for supplying data material.References
1. Doll R, Hill AB. The mortality of doctors in relation to their
smoking habits. A preliminary report. BMJ 1954;1:1451–5.
2. Centers for Disease Control and Prevention (CDC). Annual
smoking-attributable mortality, years of potential life lost,
and economic cost—United States, 1995–1999. Morb Mortal
Wkly Rep (MMWR) 2002;51:300–3.
3. Callum C. The UK smoking epidemic: deaths in 1995. London:
UK Health Education Authority; 1998.
4. Ruff LK, Volmer T, Nowak D, et al. The economic impact of
smoking in Germany. Eur Respir J 2000;16:385–90.
5. Bolin K, Lindgren B. Smoking, healthcare cost and lost
productivity in Sweden, 2001. Scand J Public Health 2007;35:
187–96.
6. Klesges RC, Johnson KC, Somes G. Varenicline for smoking
cessation. JAMA 2006;296:94–5.
7. Gonzales D, Rennard SI, Nides MA, et al. Varenicline, an a4b2
nicotinic acetylcholine receptor partial agonist, vs bupropion
and placebo for smoking cessation: a randomized controlled
trial. JAMA 2006;296:47–55.
8. Jorenby DE, Hays JT, Rigotti NA, et al. A randomized controlled
trial comparing the efﬁcacy of varenicline, a novel a4b2
nicotinic acetylcholine receptor partial agonist, to bupropion
and to placebo for smoking cessation. JAMA 2006;296:56–63.
9. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance
therapy with varenicline for smoking cessation. JAMA
2006;296:64–71.
10. Bolin K, Lindgren B, Willers S. The cost utility of bupropion in
smoking cessation health programs—simulation model results
for Sweden. Chest 2006;129:651–60.
11. Hoogendoorn M, Welsing P, Rutten-van Mo¨lken M. Cost-effec-
tiveness of varenicline compared with bupropion, NRT, and
nortriptyline for smoking cessation in the Netherlands. Curr
Med Res Opin 2008;24(1):51–61.
12. Orme ME, Hogue SL, Kennedy LM, et al. Development of the
health and economic consequences of smoking interactive
model. Tobacco Control 2001;10:55–61.
13. Nishino Y, Inoue M, Tsuji I, et al. Tobacco smoking and gastric
cancer risk: an evaluation based on a systematic review of
epidemiologic evidence among the Japanese population. Jpn J
Clin Oncol 2006;36:800–7.
14. Combe B. Early rheumatoid arthritis: strategies for prevention
and management. Best Pract Res Clin Rheumatol 2007;21:
27–42.
15. Thun MJ, Apicella LF, Jane Henley S. Smoking versus other risk
factors as the cause of smoking-attributable deaths. JAMA
2000;284(6):706–12.
16. Edelstein-Keshet L. Mathematical models in biology. Birkhauser
mathematics series. New York: Random House; 1998.17. Kuntz KM, Weinstein MC. Modelling in economic evaluation. In:
Drummond M, McGuire A, editors. Economic evaluation in
health care—merging theory with practice. Oxford: Oxford
University Press; 2001. p. 141–71.
18. Swedish National Board of Health and Welfare. Mortality by
causes. Various years.
19. Swedish National Board of Health and Welfare. Data on
inpatient care. Various years.
20. Statistics Sweden. Life tables. Various years.
21. SOU (Statens offentliga utredningar) 2003:88.
22. Bolin K, Dozet A. Smoking-related diseases: individual costs
over time. Lund University Centre for Health economics.
Manuscript.
23. La¨kemedelsstatistik AB. Medical index Sweden. Stockholm:
La¨kemedelsstatistik AB; 2002.
24. Ghatnekar O, Persson U, Glader EL, et al. Cost of stroke in
Sweden: an incidence estimate. Int J Technol Assess Health
Care 2004;20:375–80.
25. Fiscella K, Franks P. Cost-effectiveness of the transdermal
nicotine patch as an adjunct to physicians’ smoking cessation
counseling. JAMA 1996;275:1247–51.
26. Spencer M, Briggs A, Grossman R, et al. Development of an
economic model to assess the cost effectiveness of treatment
interventions for chronic obstructive pulmonary disease.
Pharmacoeconomics 2005;23:619–37.
27. Mannino DM, Buist AS, Petty TL, et al. Lung function and
mortality in the United States: data from the First National
Health and Nutrition Examination Survey follow up study.
Thorax 2003;58:388–93.
28. Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in
patients with non-small cell lung cancer. Pharmacoeconomics
2001;19:855–63.
29. Hay JW, Sterling KL. Cost effectiveness of treating low HDL-
cholesterol in the primary prevention of coronary heart disease.
Pharmacoeconomics 2005;23:133–41.
30. American Heart Association. Heart disease and stroke statis-
tics—2005 update. Dallas, Texas: American Heart Association;
2005 [&2005, American Heart Association].
31. Tengs T, Lin T. A meta-analysis of quality of life estimates for
stroke. Pharmacoeconomics 2003;21:191–200.
32. Duncan PW, Lai SM, Keighley J. Deﬁning post-stroke recovery:
implications for design and interpretation of drug trials.
Neuropharmacology 2000;39:835–41.
33. European Medicines Agency. Summary of product characterisa-
tion, 2006.
34. Willers S. Smoking cessation treatment-recommendations
for Ska˚ne, Sweden. Bakgrundsmaterial till Ska˚nelistans
rekommendationer 2007:168–73 [in Swedish]. /www.skane.se/
lakemedelsradetS.
35. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking
cessation. Cochrane Database Syst Rev 2007:CD000031.
36. Statistics Sweden. Underso¨kningar av Levnadsfo¨rha˚llanden,
1996/1997.
37. Gonzales DH, Rennard SI, Billing CB, Reeves KR, Watsky E, Gong
J. A pooled-analysis of varenicline, an alpha 4 beta 2 nicotinic
receptor partial agonist vs. bupropion, an, for smoking
cessation. SRNT 2007.
38. Wetter D, Cofta-Gunn L, Fouladi R, et al. Late relapse/
sustained abstinence among former smokers: a longitudinal
study. Prev Med 2004;39(6):1156–63.
39. Krall E, Garvey A, Garcia R. Smoking relapse after 2 years of
abstinence: ﬁndings from the VA normative aging study.
Nicotine Tob Res 2002;4:95–100.
40. Meltzer D. Accounting for future costs in medical cost-
effectiveness analysis. J Health Econ 1997;16:33–64.
41. Ekman M. Studies in health economics—modelling and data
analysis of costs and survival. Stockholm School of Economics,
2002 (Diss).
ARTICLE IN PRESS
K. Bolin et al.71042. Hjelmgren J, Berggren F, Andersson F. Health economic guide-
lines—similarities, differences, and some implications. Value
Health 2001;4:225–50.
43. Pharmaceutical Beneﬁts Board of Sweden. General guidelines
for economic evaluations. Stockholm, 2003. /www.lfn.seS.44. Lundin D, Ramsberg J. On survival consumption costs—a reply
to Nyman. Health Econ 2008;17:293–7.
45. Nyman JA. More on survival consumption costs in cost–utility
analysis. Health Econ 2006;15:319–22.
